ECSP16096477A - COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN AND A PROCEDURE FOR THEIR PREPARATION - Google Patents
COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN AND A PROCEDURE FOR THEIR PREPARATIONInfo
- Publication number
- ECSP16096477A ECSP16096477A ECIEPI201696477A ECPI201696477A ECSP16096477A EC SP16096477 A ECSP16096477 A EC SP16096477A EC IEPI201696477 A ECIEPI201696477 A EC IEPI201696477A EC PI201696477 A ECPI201696477 A EC PI201696477A EC SP16096477 A ECSP16096477 A EC SP16096477A
- Authority
- EC
- Ecuador
- Prior art keywords
- rosuvastatin
- oral administration
- ezetimiba
- procedure
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporciona una formulación compuesta sólida para la administración oral que incluye: una porción correspondiente a gránulos húmedos de ezetimiba que incluye ezetimiba que se granula por vía húmeda utilizando un granulador de lecho fluido; y una porción correspondiente a una mezcla de rosuvastatina que incluye rosuvastatina o una de sus sales farmacéuticamente aceptables.A solid composite formulation for oral administration is provided that includes: a wet granule portion of ezetimibe including ezetimibe that is wet granulated using a fluid bed granulator; and a portion corresponding to a mixture of rosuvastatin including rosuvastatin or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140078388A KR101977785B1 (en) | 2014-06-25 | 2014-06-25 | Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP16096477A true ECSP16096477A (en) | 2017-01-31 |
Family
ID=54938391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECIEPI201696477A ECSP16096477A (en) | 2014-06-25 | 2016-12-23 | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN AND A PROCEDURE FOR THEIR PREPARATION |
Country Status (10)
Country | Link |
---|---|
KR (1) | KR101977785B1 (en) |
AR (1) | AR100977A1 (en) |
BR (1) | BR112016030111A2 (en) |
CL (1) | CL2016003283A1 (en) |
EC (1) | ECSP16096477A (en) |
JO (1) | JOP20150154B1 (en) |
SG (2) | SG11201610748RA (en) |
TW (1) | TWI700100B (en) |
UY (1) | UY36190A (en) |
WO (1) | WO2015199356A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ2016538A3 (en) | 2016-09-05 | 2018-03-14 | Zentiva, K.S. | A pharmaceutical composition comprising two different active ingredients |
CZ2016539A3 (en) * | 2016-09-05 | 2018-03-14 | Zentiva, K.S. | A pharmaceutical composition comprising two different active substances and a method of its preparation |
KR102206535B1 (en) * | 2016-11-29 | 2021-01-22 | 한미약품 주식회사 | Oral composite tablet comprising ezetimibe and rosuvastatin |
EP3437636A1 (en) * | 2017-08-02 | 2019-02-06 | Adamed sp. z o.o. | Pharmaceutical composition comprising ezetimibe |
KR102500643B1 (en) * | 2019-04-18 | 2023-02-16 | 한미약품 주식회사 | Pharmaceutical combination preparation comprising ezetimibe and losartan |
KR20200137243A (en) | 2019-05-29 | 2020-12-09 | 콜마파마(주) | Process for preparation of pharmaceutical combination containing ezetimibe and rosuvastatin |
BR112022001783A2 (en) | 2019-07-31 | 2022-03-22 | Tecnimede Soc Tecnico Medicinal Sa | Immediate release multi-unit solid oral compositions, their methods and uses. |
BR112023003323A2 (en) * | 2020-08-25 | 2023-03-21 | Daewoong Pharmaceutical Co Ltd | PHARMACEUTICAL COMPOSITION IN SINGLE DOSAGE FORM |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100907144B1 (en) * | 2007-09-05 | 2009-07-09 | 박재섭 | The golf club using moving ball |
WO2009024889A2 (en) * | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
WO2011019326A2 (en) * | 2009-07-02 | 2011-02-17 | Mahmut Bilgic | Solubility and stability enchancing pharmaceutical formulation |
HUE038048T2 (en) * | 2009-07-28 | 2018-09-28 | Egyt Gyogyszervegyeszeti Gyar | New granulating process and thus prepared granulate |
EP2468258A1 (en) * | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
MX365046B (en) * | 2012-05-01 | 2019-05-17 | Althera Life Sciencies Llc | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases. |
-
2014
- 2014-06-25 KR KR1020140078388A patent/KR101977785B1/en active IP Right Grant
-
2015
- 2015-06-09 WO PCT/KR2015/005779 patent/WO2015199356A1/en active Application Filing
- 2015-06-09 SG SG11201610748RA patent/SG11201610748RA/en unknown
- 2015-06-09 SG SG10201811586YA patent/SG10201811586YA/en unknown
- 2015-06-09 BR BR112016030111A patent/BR112016030111A2/en not_active Application Discontinuation
- 2015-06-16 TW TW104119406A patent/TWI700100B/en active
- 2015-06-24 JO JOP/2015/0154A patent/JOP20150154B1/en active
- 2015-06-24 AR ARP150102016A patent/AR100977A1/en not_active Application Discontinuation
- 2015-06-24 UY UY0001036190A patent/UY36190A/en not_active Application Discontinuation
-
2016
- 2016-12-21 CL CL2016003283A patent/CL2016003283A1/en unknown
- 2016-12-23 EC ECIEPI201696477A patent/ECSP16096477A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW201625223A (en) | 2016-07-16 |
KR20160000762A (en) | 2016-01-05 |
CL2016003283A1 (en) | 2017-07-28 |
BR112016030111A2 (en) | 2017-08-22 |
WO2015199356A1 (en) | 2015-12-30 |
TWI700100B (en) | 2020-08-01 |
JOP20150154B1 (en) | 2021-08-17 |
KR101977785B1 (en) | 2019-05-14 |
UY36190A (en) | 2015-10-30 |
SG11201610748RA (en) | 2017-01-27 |
AR100977A1 (en) | 2016-11-16 |
SG10201811586YA (en) | 2019-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP16096477A (en) | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN AND A PROCEDURE FOR THEIR PREPARATION | |
CL2016002517A1 (en) | Use of r-2-4-2-ethoxy-3-4-trifluoromethylphenoxypropyl-thio-2-methylphenoxy acetic acid or a salt thereof in the manufacture of a medicament to treat a condition that is a non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. | |
CR20160191A (en) | COMPOUNDS DERIVED FROM BICYCLIC PIRIDYL FUSED TO RING AS FGFR4 INHIBITORS | |
CL2018003569A1 (en) | Fxr modulating compounds (nr1h4). | |
DOP2016000177A (en) | DERIVATIVE COMPOUNDS AND COMPOSITIONS OF N-AZASPIROCICLOALCANO N-HETEROARIL REPLACED TO INHIBIT THE ACTIVITY OF SHP2 | |
CR20150549A (en) | HETEROCYCLIC COMPOUNDS AND THEIR USES | |
CR20180253A (en) | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN UNMUNODEFICIENCY VIRUS | |
UY33370A (en) | Pharmaceutical compositions comprising a DPP4 and pioglitazone inhibitor drug, preparation and use procedures | |
EA201892415A1 (en) | POLYMORPHONE FORM | |
DOP2014000255A (en) | BICYCLICALLY REPLACED URACILES AND USE OF THE SAME | |
BR112017008993A2 (en) | Methods and Compositions Specifically for the Treatment of Attention Deficit Disorder | |
CL2014001828A1 (en) | Dual-release oral dosage system comprising doxylamine and pyridoxine and / or its analogs, metabolites and salts thereof; oral dosage form dual release; pharmaceutical kit; use to relieve symptoms of nausea and vomiting, including those of pregnancy. | |
PH12015500823A1 (en) | Modified release formulations for oprozomib | |
CL2015003468A1 (en) | Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d. | |
DOP2016000297A (en) | PHARMACEUTICAL COMPOSITIONS USEFUL TO TREAT INFECTIOUS DISEASES | |
NZ731118A (en) | Dopamine d3 receptor antagonists compounds | |
UY36124A (en) | CARBOXAMIDE DERIVATIVES | |
UY36123A (en) | CARBOXAMIDE DERIVATIVES | |
AR099943A1 (en) | CHRICAL DERIVATIVES OF 2,5-DISPOSED CYCLOPENTANCARBOXYL ACID AND ITS USE | |
CL2016000182A1 (en) | Stable anti-tuberculosis pharmaceutical composition in a form of a coated tablet comprising isoniazid granules and rifapentin granules and their preparation process | |
BR112016015175A2 (en) | PHARMACEUTICAL FORMULATION, METHOD FOR MANUFACTURING A PHARMACEUTICAL FORMULATION COMPRISING SILDENAFIL AND CLOMIPRAMINE AND TABLET | |
EA201991359A1 (en) | PHARMACEUTICAL MEDICINAL FORMS | |
AR100153A1 (en) | MEDICINE | |
CL2015003780A1 (en) | Pyrimido-isoquinolin-quinone derivative compounds, their salts, isomers, acceptable pharmaceutical tautomers; farm compositions; preparation procedure; and its use in the treatment of multiresistant bacterial and bacterial diseases. | |
PE20170130A1 (en) | (S) - PIRLINDOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE |